Compare Ginkgo Bioworks Holdings Inc (DNA) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Noble Corporation plc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Noble Corporation plc trades at $41.59 (market cap $6.65B). The key difference: Noble Corporation plc is far larger — about 11.3× Ginkgo Bioworks Holdings Inc's market cap, and Noble Corporation plc pays a 4.8% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | NE | |
|---|---|---|
Market Cap | $590.53M | $6.65B |
Sector | Health | Technology |
52-Week High | $16.14 | $54.37 |
52-Week Low | $5.48 | $25.70 |
Enterprise Value | $627.78M | $7.90B |
Dividend Yield | — | 4.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Noble Corporation (NE) trades at $41.79, up 4.55% with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with $3.29B revenue, 7.17% net margin, and positive cash flow of $228M in 2025. Recent contract wins in Brunei and the UK Continental Shelf worth over $136M demonstrate operational momentum ahead of Q2 2026 earnings on July 27.
Analyst consensus suggests moderate upside with a $50 price target, though mixed earnings history and elevated P/E of 29.15 warrant caution. Key risks include offshore drilling market volatility and execution on new contracts, while institutional sentiment remains divided with 31% buy ratings versus 25% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
